PATENT CLAIM ANALYSIS

Application Number: 15777222
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-06
Patent Classification: ["514", "017800"]

Abstract:
The present invention is directed to a composition for intranasal administration comprising a CDNF polypeptide for use in the intranasal treatment of a central nervous system disease, such as Alzheimer's disease, Parkinson's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, dementia with Lewy bodies, mild cognitive impairment, Huntington's disease, traumatic brain injury and stroke. The present invention is also directed to a composition for intranasal administration comprising a MANF polypeptide for use in the intranasal treatment of a central nervous system disease.

Claim (Index 57):
The method according to  claim 55 , wherein said composition is a liquid or powder.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 93.0
- Lexical Diversity: 1.84906
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14480975', '12433345', '15335027', '15436050', '14383311']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7918300482132642
- 35 USC 102 Novelty (BERT): 0.5364321185682264
- Combined Prediction Score: 0.7662902552487604
- Mean Citation Score: 307.14936
- Max Citation Score: 370.89774
- Similarity Product: 225.4397180569876

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test